NO20064896L - Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer - Google Patents

Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer

Info

Publication number
NO20064896L
NO20064896L NO20064896A NO20064896A NO20064896L NO 20064896 L NO20064896 L NO 20064896L NO 20064896 A NO20064896 A NO 20064896A NO 20064896 A NO20064896 A NO 20064896A NO 20064896 L NO20064896 L NO 20064896L
Authority
NO
Norway
Prior art keywords
treatment
autoimmune
procedures
inflammatory diseases
autoimmune diseases
Prior art date
Application number
NO20064896A
Other languages
English (en)
Other versions
NO340627B1 (no
Inventor
Marie Kosco-Vilbois
Bernard Mach
Yann Dean
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of NO20064896L publication Critical patent/NO20064896L/no
Publication of NO340627B1 publication Critical patent/NO340627B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

S a m m e n d r a g Denne oppfinnelse tilveiebringer fremgangsmåter for behandling av autoimmune sykdommer og/eller inflammatoriske lidelser.
NO20064896A 2004-04-06 2006-10-26 Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff. NO340627B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55994404P 2004-04-06 2004-04-06
PCT/US2005/011767 WO2005099755A2 (en) 2004-04-06 2005-04-06 Methods of treating autoimmune and inflammatory diseases

Publications (2)

Publication Number Publication Date
NO20064896L true NO20064896L (no) 2006-11-06
NO340627B1 NO340627B1 (no) 2017-05-15

Family

ID=35150504

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20064896A NO340627B1 (no) 2004-04-06 2006-10-26 Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff.
NO20170737A NO20170737A1 (no) 2004-04-06 2017-05-04 Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20170737A NO20170737A1 (no) 2004-04-06 2017-05-04 Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff

Country Status (19)

Country Link
US (1) US20050265993A1 (no)
EP (1) EP1737490B1 (no)
JP (1) JP4812748B2 (no)
KR (1) KR20070036035A (no)
CN (2) CN1972714B (no)
AT (1) ATE470453T1 (no)
AU (1) AU2005232653B2 (no)
CA (1) CA2563260C (no)
DE (1) DE602005021766D1 (no)
DK (1) DK1737490T3 (no)
EA (1) EA012725B1 (no)
ES (1) ES2348984T3 (no)
IL (2) IL178478A (no)
MX (1) MXPA06011526A (no)
NO (2) NO340627B1 (no)
PT (1) PT1737490E (no)
UA (2) UA89780C2 (no)
WO (1) WO2005099755A2 (no)
ZA (1) ZA200608884B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939899B2 (ja) * 2006-10-30 2012-05-30 オムロンオートモーティブエレクトロニクス株式会社 導電端子の溶接方法、および導電端子構造
WO2008119567A2 (en) † 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2575971B1 (en) * 2010-05-24 2015-12-16 Indena S.p.A. Combined plant extracts for use in the treatment of microbial infections
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
US9664690B1 (en) * 2013-08-28 2017-05-30 The National Institute For Biotechnology I Molecular diagnostic kits for evaluating stress
CA3095134A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in dna isolated from exosomes
EP3866831A4 (en) * 2018-10-16 2022-08-24 Board of Regents, The University of Texas System IDENTIFICATION AND TARGETING OF PATHOGENIC EXTRACELLULAR MATRIX FOR DIAGNOSIS AND TREATMENT OF CANCER AND OTHER DISEASES
EP3873521A2 (en) * 2018-10-31 2021-09-08 Tiziana Life Sciences PLC Composition and methods of treating inflammatory and autoimmune diseases
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US7041289B1 (en) * 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
JP2007538000A (ja) * 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性ｔ細胞は自己免疫を抑制する

Also Published As

Publication number Publication date
MXPA06011526A (es) 2007-03-21
DE602005021766D1 (de) 2010-07-22
KR20070036035A (ko) 2007-04-02
ATE470453T1 (de) 2010-06-15
UA89780C2 (ru) 2010-03-10
NO340627B1 (no) 2017-05-15
AU2005232653B2 (en) 2010-12-16
NO20170737A1 (no) 2006-11-06
CN102847149B (zh) 2016-01-20
JP4812748B2 (ja) 2011-11-09
WO2005099755A2 (en) 2005-10-27
WO2005099755A3 (en) 2006-04-27
EP1737490B1 (en) 2010-06-09
IL178478A (en) 2010-12-30
CN1972714B (zh) 2012-10-03
PT1737490E (pt) 2010-08-31
UA103594C2 (ru) 2013-11-11
ES2348984T3 (es) 2010-12-21
IL178478A0 (en) 2007-02-11
EP1737490A2 (en) 2007-01-03
ZA200608884B (en) 2008-06-25
IL209338A0 (en) 2011-01-31
CN1972714A (zh) 2007-05-30
US20050265993A1 (en) 2005-12-01
AU2005232653A1 (en) 2005-10-27
CA2563260A1 (en) 2005-10-27
EA012725B1 (ru) 2009-12-30
JP2007532565A (ja) 2007-11-15
CA2563260C (en) 2013-05-28
HK1099525A1 (en) 2007-08-17
CN102847149A (zh) 2013-01-02
DK1737490T3 (da) 2010-10-04
EA200601871A1 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
IS8451A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
IS8410A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
DK1836169T3 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
IL209338A0 (en) Pharmaceutical compositions containing anti-cd-3 antibodies
NO20034056D0 (no) Proliferative sykdommer
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
DK1809280T3 (da) Mitotiske kinesininhibitorer og fremgangsmåder til anvendelse deraf
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
NO20072285L (no) S-mirtazapin for behandling av hetetokter
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
IS8497A (is) Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
DK1896077T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme
NL1030418A1 (nl) Azabenzoxazolen voor de behandeling van CZS-stoornissen.
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
DK1919290T3 (da) Fremgangsmåder og produkter til behandling af sygdomme
NO20055309D0 (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof